Every material Form 8-K Aktis Oncology, Inc. has filed with the SEC since April 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aktis Oncology reported second-quarter 2026 results for the period ended June 30, 2026. Collaboration revenue rose to $3.4 million from $1.6 million, but higher research and development and general and administrative spending widened the net loss to $24.1 million from $18.1 million, and the company's cash position rose to $517.3 million after its January 2026 initial public offering.
Net loss was $24.1 million for the quarter, compared with $18.1 million a year earlier.
Collaboration revenue was $3.4 million, compared with $1.6 million a year earlier, tied to the Eli Lilly and Company research collaboration.
Research and development expenses rose to $25.3 million from $18.6 million, and general and administrative expenses rose to $7.0 million from $3.9 million.
Cash, cash equivalents, and marketable securities were $517.3 million at June 30, 2026, which the company says will fund its operating plan into 2029.
Aktis Oncology reported first-quarter 2026 results in an 8-K furnished with a press release. Collaboration revenue rose to $3.2 million from $1.4 million a year earlier, but the net loss widened to $18.3 million from $15.0 million as research and development and general and administrative expenses increased. Cash, cash equivalents and marketable securities reached $538.5 million at March 31, 2026, which the company says will fund operations into 2029.
Collaboration revenue was $3.2 million for the quarter ended March 31, 2026, versus $1.4 million a year earlier, tied to the Eli Lilly research collaboration.
Net loss was $18.3 million versus $15.0 million; R&D expenses rose to $20.0 million from $15.9 million and G&A expenses rose to $5.9 million from $3.7 million.
Cash, cash equivalents and marketable securities were $538.5 million at March 31, 2026, up from $226.8 million at December 31, 2025, mainly due to net proceeds from the January 2026 initial public offering.
Aktis Oncology appointed Glenn Gormley, MD, PhD, a former Daiichi Sankyo executive, as a director effective April 15, 2026, and named him co-chair of a newly created Science and Technology Committee. Directors Helen S. Kim and Oleg Nodelman will leave the board effective May 20, 2026, and the company said their resignations are not due to any disagreement with the company.
Gormley appointed as a Class I director effective April 15, 2026, with a term expiring at the 2027 annual meeting; he is co-chair of the Science and Technology Committee with Ken Herrmann, MD, PhD
Non-employee director pay: $45,000 per year for board service and $15,000 per year for committee co-chair service, prorated for the year
Gormley granted an option on April 15, 2026 to buy up to 37,866 shares of common stock, vesting in equal annual installments over three years
Helen S. Kim and Oleg Nodelman resign from the board and all committees effective May 20, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aktis Oncology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →